EVOLUS, INC. Deferred Tax Asset, Interest Carryforward
EVOLUS, INC. (EOLS) had Deferred Tax Asset, Interest Carryforward of $11.47 million as of 2025-12-31, per its 10-K filed 2026-03-03.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetInterestCarryforward · last filed 2026-03-03
- 2025-12-31: Deferred Tax Asset, Interest Carryforward $11.47M.
- 2024-12-31: Deferred Tax Asset, Interest Carryforward $8.32M.
- 2023-12-31: Deferred Tax Asset, Interest Carryforward $5.07M.
| Period end | Deferred Tax Asset, Interest Carryforward |
|---|---|
| 2025-12-31 | $11.47M 10-K · filed 2026-03-03 |
| 2024-12-31 | $8.32M 10-K · filed 2026-03-03 |
| 2023-12-31 | $5.07M 10-K · filed 2026-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |